Triflusal

Triflusal Basic information
Pharmacological Study
Product Name:Triflusal
Synonyms:2-acetoxy-4-trifluoromethylbenzoic acid;3-acetoxy-alpha,alpha,alpha-trifluoro-p-toluic acid;4-cresoticacid,alpha,alpha,alpha-trifluoro-acetate;4-trifluoromethylsalicylicacidacetate;alpha,alpha,alpha-trifluoro-2,4-creosoticacidacetate;ur1501;4-CRESOTIC ACID, ALPHA,ALPHA,ALPHA-TRIFLUORO- ACETATE, 99+%;TRIFLUOROTRIMESICACID
CAS:322-79-2
MF:C10H7F3O4
MW:248.16
EINECS:206-297-5
Product Categories:Aromatics;Drug Analogues;APIs;I;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:322-79-2.mol
Triflusal Structure
Triflusal Chemical Properties
Melting point 120-122° (upon slow heating); 110-112° (upon quick heating)
Boiling point 316.0±42.0 °C(Predicted)
density 1.433±0.06 g/cm3(Predicted)
storage temp. Sealed in dry,2-8°C
solubility DMSO: >30mg/mL
form powder
pka2.97±0.10(Predicted)
color white to off-white
λmax297nm(H2O)(lit.)
Merck 14,9688
CAS DataBase Reference322-79-2(CAS DataBase Reference)
Safety Information
Hazard Codes Xn
Risk Statements 22-36/37/38-43
Safety Statements 26-36/37
WGK Germany 3
RTECS GP4250000
HS Code 2918.29.7500
MSDS Information
Triflusal Usage And Synthesis
Pharmacological StudyTriflusal is an antiplatelet agent structurally related to the salicylates, but it is not derived from ASA. Triflusal and its metabolite (3-hydroxy-4-triuoro-methylbenzoic acid or HTB) produce specific inhibition of platelet arachidonic acid metabolism (McNeely and Goa, 1998). A single 12-month open-label trial of tritriflusal in 73 VaD patients (López-Pousa et al., 1997) showed fewer declines in MMSE scores in the active group compared with untreated subjects. More recently, triusal was used in patients with amnesic MCI; 257 patients were randomized to receive 900 mg of triflusal or placebo for 18 months. Triflusal therapy was associated with a signicantly lower rate of conversion to dementia (Gómez-Isla et al., 2008).
DescriptionTriflusal is an antiplatelet agent structurally related to the salicylates, but it is not derived from ASA. Triflusal and its metabolite (3-hydroxy-4-triuoro-methylbenzoic acid or HTB) produce specic inhibition of platelet arachidonic acid metabolism (McNeely and Goa, 1998). A single 12-month open-label trial of Triflusal in 73 VaD patients (López-Pousa et al., 1997) showed fewer declines in MMSE scores in the active group compared with untreated subjects. More recently, Triflusal was used in patients with amnesic MCI; 257 patients were randomized to receive 900 mg of Triflusal or placebo for 18 months. Triflusal therapy was associated with a signicantly lower rate of conversion to dementia (Gómez-Isla et al., 2008).
Chemical PropertiesWhite to Off-White Solid
UsesAn analog of Aspirin; inhibits platelet aggregation. Antithrombotic.
UsesAntithrombotic;Cyclooxygenase inhibitor
DefinitionChEBI: 2-acetyloxy-4-(trifluoromethyl)benzoic acid is a member of salicylates, a carboxylic ester and a member of benzoic acids.
Mechanism of action2-hydroxy-4-trifluoromethylbenzoic acid (HTB), the deacetylated metabolite of triflusal, retains significant antiplatelet activity. Triflusal is rapidly absorbed and metabolized. The area under the concentration–time curve for triflusal is 20.26 mg/L/hour after a 900-mg dose, whereas that for HTB is 42.27 mg/L/hour. Much of the pharmacokinetic data for triflusal activity is associated with HTB. The inhibition of COX, as measured by reduced production of thromboxane B2, is 25% after 2 hours and 85% after 7 days with triflusal, whereas the effects of aspirin on thromboxane B2 is more than 90% reduction after 2 hours and is maintained at this level after 7 days. It would appear that the presence of a 4-trifluoromethyl group also greatly enhances triflusal's ability to inhibit the activation of nuclear factor κB, which in turn regulates the expression of the mRNA of vascular cell adhesion molecule-1 needed for platelet aggregation. In addition, triflusal increases nitric oxide synthesis in neutrophils, which results in an increased vasodilatory potential. Finally, an additional site of action for triflusal/HTB is the inhibition of cAMP phosphodiesterase, leading to increased levels of cAMP. Elevated cAMP levels decrease platelet aggregation through decreased mobilization of calcium. Aspirin and salicylic acid do not significantly increase cAMP levels.
Clinical UseTriflusal (2-acetoxy-4-trifluoromethyl benzoic acid) is an antiplatelet drug that despite its structural similarity to aspirin exhibits quite different pharmacological and pharmacokinetic properties.
Triflusal Preparation Products And Raw materials
Preparation Productsacetate-->4-Trifluoromethylsalicylic acid
Amitriptyline hydrochloride Regorafenib Albuterol sulfate Trifluoromethanesulfonic acid Imatinib Tazarotene FLUOROSULFONIC ACID Tamoxifen citrate 4-Methylsalicylic acid Acetylsalicylic acid 2-METHOXY-4-(TRIFLUOROMETHYL)BENZALDEHYDE 4-Trifluoromethylsalicylic acid 4-(Trifluoromethyl)benzoic acid p-Toluic acid 2-METHOXY-4-METHYLBENZOIC ACID 3-(TRIFLUOROMETHYL)PHENYL ACETATE Benzoic acid Triflusal

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.